CAL-101 has far less efficacy on marrow disease

[Guest guest]

Elevated ALC are not likely to be a huge issue, they seem to resolve over time

and lymphocytosis is not likely to cause too much trouble by way of explaining

the results due to CAL-101.

Potentially unresolved bone marrow infiltration is a much bigger problem, unless

it is PROVEN not to be the case.

Dr. Furman, I quote you from the reference below, " CAL-101 seems to have far

less efficacy on bone marrow disease, which has taught us a great deal about the

molecular pathways involved in lymphocyte trafficking, including CXCR4 and

CXCL12. "

Surely we need well defined clinical trial results to better understand these

issues before we get ready to take apart regulatory agencies.

Advances in LLM

Edited by Dr. O'Brien

New Agents in Early Clinical Trials for CLL Therapy

By Dr. R. Furman

http://www.clinicaladvances.com/article_pdfs/ho-article-201007-llm.pdf

>

> But do remember not to underestimate " response " for some of the drugs we are

discussing. The PCI-32765 and CAL-101 patients, even with complete regression

of lymphadenopathy may not qualify asonre responders because of the

lymphocytosis. These patients are clearly benefiting even as non-responders.

>

> Rick Furman

>

>